Borget I,Vielh P, Schlumberger M, De Pouvourville G Gustave Roussy Institute, Villejuif, France OBJECTIVES: The prevalence of thyroid nodules is high with four to seven percent in the general population. Fine-needle aspiration cytology (FNA-t) is recommended as the reference test because it is minimally invasive, presents an optimal positive predictive value and is cost-effective when compared to whole-bodyscan (WBS). The diagnosis is known for the fraction of patients operated. Suspicious findings are a dilemma. For benign and indeterminate results, a long-term follow-up delayed the time of diagnosis. This study aims to determine the total cost of a true diagnosis by FNA-t. The model takes account of false-positive, false-negative, suspicious and indeterminate results. METHODS: A Markov model was built describing the trajectory and the management of patients, from the first FNA-t and until a conclusive diagnosis was obtained. We derived estimates for patient, diagnostic accuracy values and follow-up from a retrospective study, including patients who had their first FNA-t in 2003 or 2004. Costs were computed from the viewpoint of the hospital. A microcosting study was assessed to determine the unit cost of FNA-t. Costs of hospital stays for surgery were extracted from the hospital cost accounting. Sensitivity analyses were performed. RESULTS: A total of 105/390 patients were operated. Specificity and sensitivity values were respectively 86% and 78%. The unit cost of FNA-t was estimated to €118. Markov modeling showed that the mean total cost of a true diagnosis was €997 per patient, including unnecessary surgeries, FNA-t and follow-up. Cost decreased with the capacity of the cytologist to minimize indeterminate results. CONCLUSION: The true cost of a given procedure exceeds its unit cost of production. This result is conditional to the performance of the cytologist and is highly dependent on the 29% of indeterminate results. Ultrasound-guidance would reduce this rate and the true cost by a great deal at a relatively low unit cost.
PEN2 COST COMPARISON OF HUMAN GROWTH HORMONE DELIVERED VIA PEN DEVICES AND VIAL/SYRINGE IN PEDIATRIC PATIENTS: A BUDGETARY IMPACT MODEL
Bazalo GR 1 , Joshi AV 2 , Germak JA 3 1 Managed Solutions, LLC, Conifer, CO, USA, 2 Novo Nordisk Pharmaceuticals, Inc, Princeton, NJ, USA, 3 Novo Nordisk Pharmaceuticals, Princeton, NJ, USA OBJECTIVE: To assess the economic impact to the US payer of recombinant human growth hormone (rHGH) utilization in a pediatric population. METHODS: rHGH may be administered to pediatric patients via vial/syringe or pen injection systems provided by six manufacturers. Variation in annual drug cost is largely a function of dosing efficiency and price per milligram (mg). A budgetary impact model was developed to calculate drug costs based on product waste and cost. Waste was calculated as the difference between prescribed dose, based on patient weight, and actual delivered dose, based on dosing increments and maximum deliverable dose for pens and a fixed percent waste as derived from the literature for vials. Annual drug costs were calculated based upon total mg delivered, using a daily dose of 0.03 mg/kg and wholesale acquisition cost. Total annual drug costs, assuming equal use of vials and pens from each manufacturer, were compared for two scenarios: 1) A mix based on national market share and 2) restricting use to the product with lowest waste. RESULTS: Based on the literature, waste for each vial product was 23%, including injection error (15%) and syringe/needle dead space (8%). Among individual pens, waste was highest for Humatrope 24 mg (19.5%) and lowest for Norditropin NordiFlex 5 mg (1.1%). Equal use of vials and pens from each manufacturer resulted in the following product waste: Tev-Tropin 23% (vial only), Nutropin 18.4%, Humatrope 14.5%, Genotropin 7.1%, Saizen 4.6%, and Norditropin 3.6%. Restricting use to the product with least waste (Norditropin) resulted in an 11.0% reduction in annual patient cost from $19,196 to $17,089 compared to national share mix. CON-CLUSION: Pen delivery systems result in less waste than vial and syringe. Considering all approved delivery systems, Norditropin resulted in the least product waste and lower annual patient cost.
PEN3 COST COMPARISON OF HUMAN GROWTH HORMONE DELIVERED VIA PEN DEVICES VERSUS VIAL/SYRINGE IN ADULT PATIENTS: A BUDGETARY IMPACT MODEL
Bazalo GR 1 , Joshi AV 2 , Germak JA 3 1 Managed Solutions, LLC, Conifer, CO, USA, 2 Novo Nordisk, Inc, Princeton, NJ, USA, 3 Novo Nordisk Pharmaceuticals, Princeton, NJ, USA OBJECTIVE: To assess the economic impact to the US payer of recombinant human growth hormone (rHGH) utilization in an adult population. METHODS: rHGH may be administered to adults via vial/syringe or pen injection systems provided by six manufacturers. Variation in annual drug cost is largely a function of dosing efficiency and price per milligram (mg). A budgetary impact model was developed to calculate drug costs based on product waste and cost. Waste was calculated as the difference between prescribed dose, based on patient weight, and actual delivered dose, based on dosing increments and maximum deliverable dose for pens and a fixed percent waste as derived from the literature for vials. Annual drug costs were calculated based upon total mg delivered, using a daily dose of 0.016 mg/kg and wholesale acquisition cost. Total annual drug costs, assuming equal use of vials and pens from each manufacturer, were compared for two scenarios: 1) A mix based on national market share and 2) restricting use to the product with lowest waste.
RESULTS:
Based on the literature, waste for each vial product was 23%, including injection error (15%) and syringe/needle dead space (8%). Among individual pens, product waste was highest for Humatrope 24 mg (14.3%) and lowest for Norditropin NordiFlex 5 mg (1.0%). Equal use of vials and pens from each manufacturer resulted in the following product waste: Tev-Tropin 23% (vial only), Nutropin 18.2%, Humatrope 12.2%, Genotropin 5.5%, Saizen 3.8%, and Norditropin 3.0%. Restricting use to the product with least waste (Norditropin) resulted in a 10.5% reduction in annual patient cost from $24,764 to $22,161 compared to a national share mix. CON-CLUSION: Pen delivery systems result in less waste than vial and syringe. Considering all approved delivery systems, Norditropin resulted in the least product waste and lower annual patient cost.
PEN4 EVALUATION OF THE ASSOCIATION BETWEEN THE QUALITY OF LIFE, SOCIAL CLASS AND HEIGHT IN THE GENERAL ADULT UK POPULATION
Christensen T 1 , Djuurhus C 1 , Andersen S 2 , Kragh N 2 , Clayton P 3 , Christiansen J 4 1 Novo Nordisk, Bagsvaerd, Denmark, 2 University of Southern Denmark, Odense, Denmark, 3 University of Manchester, Manchester, UK, 4 Århus University Hospital, Århus, Denmark OBJECTIVES: Short stature has been shown to influence social factors during childhood and adult life. However, limited data exist to determine the influence of short stature on Health Related Quality Of Life (HRQOL) due to underpowered studies and the fact that children find questionnaires very hard to complete. The objective of this study was to characterize the influence of height on social class and HRQOL for the general adult population in UK. METHODS: The Health Survey for England (HSE03) was commissioned by the Department of Health and collected data during the period 2003 to 2004. HSE03 consisted of a random population sample in England. Observations for 14,416 adults (age >18 years) were included in the analysis. The survey involved a questionnaire-based interview followed by a nurse visit, where measurements and blood samples were taken. HRQOL was measured using the EQ-5D questionnaire. Social class (I-V) were derived according to definition from UK National Statistics. Height was converted from centimetres to height percentiles (0%-100%) to obtain standardized scores. RESULTS: A regression analysis showed increasing height had a significant influence on increasing HRQOL. The largest HRQOL differences were observed in the shorter groups. An ANOVA showed HRQOL for the shortest 2.5% (EQ-5D = 0.791) was significantly reduced (P = 0.007) compared with all other persons (EQ-5D = 0.873). The data showed a trend towards increasing height having an influence on number of persons in social class I + II. However, this trend could not account for the relationship between height and HRQOL in the shorter subgroups. CON-CLUSIONS: Short stature negatively impacts upon HRQOL and does this independently of social class. The impact of height on HRQOL was largest in the shorter height subgroups. Effects of distinct causes of short stature can not be excluded, however statistically the majority of short persons will have idiopathic short stature. April 25, 2006 , and screened reference lists of eligible trials. Randomized trials were included if comparing lamivudine plus interferon-alpha with lamivudine alone in patients with HBeAg-positive and ALT-elevated CHB. We recorded interventional and patient characteristics. Quality of trials was assessed by six items based on the Cochrane recommendation. We used fixed and random effect model meta-analysis to pool the data. Two types of interventional strategies were available: a) lamivudine in both arms were administrated 52 weeks; and b) lamivudine was administrated 24 weeks in combination arm while 52 weeks in monotherapy. We stratified trials for analysis, and performed sensitivity analysis based on the dose of interferon-alpha, where appropriate. RESULTS: Twenty randomized trials were included. Quality was moderate in most. Both at 24-week (for both types) and 52-week (for type b) of treatment, loss of HBeAg (RR = 2.54 and 1.62, 95%CI = 1.91-3.37; 1.13-2.33, p = 0.000 and 0.009) and HBeAg seroconversion (RR = 3.12 and 1.73, 95%CI = 2.07-4.70; 1.20-2.51, p = 0.000 and 0.004) were significantly higher in combination than lamivudine monotherapy. Loss of HBV DNA, loss of HBsAg and normalization of ALT were not statistically significant. Two strategy types were limited in follow-up data. However, loss of HBV DNA was significantly higher in combination group after a 26-week follow-up in both strategies; no significant difference was found in serological and biomedical markers. CONCLUSIONS: It was suggested that combination therapy might be superior to lamivudine therapy in clearing serological markers but not for virological and biomedical ones during treatment. Further study was needed to investigate the long-term benefit of combination therapy.
GI DISORDERS PGI1 IS COMBINATION THERAPY OF LAMIVUDINE WITH INTERFERON-ALPHA SUPERIOR TO LAMIVUDINE MONOTHERAPY FOR HBEAG-POSITIVE CHRONIC HEPATITIS B? A META-ANALYSIS OF RANDOMIZED TRIALS

PGI2 PROTON PUMP INHIBITORS FOR THE TREATMENT OF REFLUX OESOPHAGITIS: ENDOSCOPIC HEALING RATES FROM A SYSTEMATIC REVIEW OF RANDOMISED CONTROLLED TRIALS
Edwards SJ 1 , Lind T 2 , Lundell L 3 1 AstraZeneca UK Ltd, Luton, Bedfordshire, UK, 2 AstraZeneca R&D Mölndal, Mölndal, Västra Götaland, Sweden, 3 Karolinska University Hospital, Stockholm, Huddinge, Sweden OBJECTIVES: To compare the efficacy of esomeprazole with the European licensed standard dose of PPIs for the endoscopic healing of reflux oesophagitis (i.e. esomeprazole 40 mg compared with lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg, and rabeprazole 20 mg). METHODS: Systematic review of CENTRAL, BIOSIS, EMBASE and MEDLINE for randomised controlled trials (RCTs) in patients with reflux oesophagitis was conducted in February 2005. Data on endoscopically verified healing rates at four and eight weeks were extracted and
